Investors

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Global Blood Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the compensation committee of the Company’s board of directors granted two new employees inducement grants.

The first employee received an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $39.25, the closing trading price on the grant date of November 28, 2017. The second employee received an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $37.40, the closing trading price on the grant date of November 29, 2017. Additionally, each of the two employees received a restricted stock unit award for 10,000 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees’ entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_news

Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
investor@globalbloodtx.com

Julie Normart (media)
Pure Communications
415-946-1087
media@globalbloodtx.com

Primary Logo

Global Blood Therapeutics, Inc.